Can ‘Long-Term Partner’ Cipla Breathe New Life Into MannKind’s Afrezza?

Cipla is to commercialize the financially troubled MannKind’s inhaled insulin Afrezza in India, but it remains to be seen whether the deal can materially change the fortunes of the product.